Bayer gets shareholder rebuke for management remuneration
Reuters
Published Apr 29, 2022 12:51PM ET
FRANKFURT (Reuters) - Shareholders of Bayer (OTC:BAYRY) on Friday voted to reprimand the German drug and farming supplies maker for its top management pay scheme, after one leading proxy advisory group said it did not adequately reflect Bayer's litigation burden.
At Friday's annual general meeting, 75.89% of shareholders voted against approval of the report on executive board compensation.
In the run-up to the vote, advisory firm Glass Lewis wrote in a report that it took issue with how Bayer adjusted a management payout component that is contingent on group cash flow to strip out the effect of major litigation.
Settlements of U.S. claims that weedkiller Roundup causes cancer have cost Bayer billions. Bayer has repeatedly said that the product is safe to use, which has been confirmed by U.S. and European environmental regulators.
"We find the impact of litigations should be accounted for in management board's remuneration outcomes," Glass Lewis said in the report at the time.
Even tough the vote has no direct legal consequences, it marks another setback in Bayer's shareholder relations after investors in 2019 voted to disapprove of how Chief Executive Werner Baumann and his top team had managed the company.
Investors took issue at the time with how Bayer handled lawsuits related to Roundup, a product inherited as part of the 2018 takeover of Monsanto (NYSE:MON).
Bayer's executive board, however won clear votes of confidence from shareholders at last year's annual general meeting (AGM) and in 2020.
Shareholders on Friday voted 82% in favour of the executive board's actions during the past business year.
In Germany management compensation resolutions are not legally binding, and the supervisory board remains responsible for setting the compensation of the management board irrespective of this shareholders' vote.
Norway's $1.3 trillion wealth fund, which holds 2.27% in Bayer, said this month it would vote against the remuneration package.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.